Ключевые слова
Helicobacter pylori
progress
tumor heterogeneity
Как цитировать
Аннотация
Gastric carcinoma is the fourth most common malignancy and the second leading cause of cancer death worldwide. Stomach cancer kills many people in the world, so studying its initiation and development is very important. Diagnosing gastric cancer is directly related to timely endoscopic research. However, it is also important that most cases are already in the late stage due to the scarcity of early symptoms. Gastric cancer is a heterogeneous disease and is represented by different phenotypes, genotypes, complexity of the clinical course and low sensitivity to treatment. The heterogeneity of gastric cancer is due to many factors, which include genetic, environmental and various infectious agents. Most cases of stomach cancer are associated with Helicobacter pylori. Understanding the etiologic, epidemiologic, and various risk factors is essential for the timely diagnosis of gastric cancer and subsequent targeted treatment. Analysing the function of signalling pathways is important for developing personalised medicine. Since a rather heterogeneous genotype and phenotype characterise gastric cancer, it is, therefore, necessary to conduct more studies that include molecular-genetic analysis of cases, as this will help to detect the lesion at an early stage and subsequently manage individual cases better. And improving the patient's quality of life.
Библиографические ссылки
Z. Peng, C.-X. Wang, E.-H. Fang, G.-B. Wang, and Q. Tong, ‘Role of epithelial-mesenchymal transition in gastric cancer initiation and progression.’, World J Gastroenterol, vol. 20, no. 18, pp. 5403–10, May 2014, doi: 10.3748/wjg.v20.i18.5403.
‘ https://gco.iarc.who.int/en’.
C. D. Iwu and C. J. Iwu-Jaja, ‘Gastric Cancer Epidemiology: Current Trend and Future Direction’, Hygiene, vol. 3, no. 3, pp. 256–268, Jul. 2023, doi: 10.3390/hygiene3030019.
‘https://www.ncdc.ge/#/pages/file/3d9d1b31-4198-4127-90bb-41db1b80aa63’.
P. Correa, ‘Gastric cancer: overview.’, Gastroenterol Clin North Am, vol. 42, no. 2, pp. 211–7, Jun. 2013, doi: 10.1016/j.gtc.2013.01.002.
‘https://www.pathologyoutlines.com/topic/stomachcarcinomageneral.html’.
O. I. Crețu, A. E. Stepan, C. E. Simionescu, D. Marinescu, and M. D. Stepan, ‘Classification and Grading Systems in Gastric Adenocarcinomas.’, Curr Health Sci J, vol. 48, no. 3, pp. 284–291, 2022, doi: 10.12865/CHSJ.48.03.06.
E. C. Smyth et al., ‘Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.’, Ann Oncol, vol. 27, no. suppl 5, pp. v38–v49, Sep. 2016, doi: 10.1093/annonc/mdw350.
J. Machlowska, J. Baj, M. Sitarz, R. Maciejewski, and R. Sitarz, ‘Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies’, Int J Mol Sci, vol. 21, no. 11, p. 4012, Jun. 2020, doi: 10.3390/ijms21114012.
Muzaheed, ‘Helicobacter pylori Oncogenicity: Mechanism, Prevention, and Risk Factors’, 2020, Hindawi Limited. doi: 10.1155/2020/3018326.
H. J. Ahn and D. S. Lee, ‘Helicobacter pylori in gastric carcinogenesis’, World J Gastrointest Oncol, vol. 7, no. 12, pp. 455–465, Dec. 2015, doi: 10.4251/wjgo.v7.i12.455.
F. Armando, F. Mazzola, L. Ferrari, and A. Corradi, ‘An Overview of Epithelial-to-Mesenchymal Transition and Mesenchymal-to-Epithelial Transition in Canine Tumors: How Far Have We Come?’, Jan. 01, 2023, MDPI. doi: 10.3390/vetsci10010019.
Z. Peng, C.-X. Wang, E.-H. Fang, G.-B. Wang, and Q. Tong, ‘Role of epithelial-mesenchymal transition in gastric cancer initiation and progression.’, World J Gastroenterol, vol. 20, no. 18, pp. 5403–10, May 2014, doi: 10.3748/wjg.v20.i18.5403.
M. K. Joo, ‘Aberrant expression of epithelial-mesenchymal transition markers in early gastric cancer: Clinical application’, Sep. 01, 2019, Korean Society of Gastrointestinal Endoscopy. doi: 10.5946/ce.2019.139.
N.-Y. Chia and P. Tan, ‘Molecular classification of gastric cancer.’, Ann Oncol, vol. 27, no. 5, pp. 763–9, May 2016, doi: 10.1093/annonc/mdw040.
Z.-N. Lei et al., ‘Signaling pathways and therapeutic interventions in gastric cancer’, Signal Transduct Target Ther, vol. 7, no. 1, p. 358, Oct. 2022, doi: 10.1038/s41392-022-01190-w.
S. H. Seo et al., ‘Ki-67 labeling index as a prognostic marker in advanced stomach cancer’, Ann Surg Treat Res, vol. 96, no. 1, pp. 27–33, Jan. 2019, doi: 10.4174/astr.2019.96.1.27.
L. F. Abrahao-Machado and C. Scapulatempo-Neto, ‘HER2 testing in gastric cancer: An update.’, World J Gastroenterol, vol. 22, no. 19, pp. 4619–25, May 2016, doi: 10.3748/wjg.v22.i19.4619.
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
Copyright (c) 2024 Georgian Scientists